Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) EBT: 2020-2025

Historic EBT for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to $621,000.

  • Xeris Biopharma Holdings' EBT rose 103.26% to $621,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.6 million, marking a year-over-year increase of 76.16%. This contributed to the annual value of -$57.1 million for FY2024, which is 10.08% up from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported EBT of $621,000 as of Q3 2025, which was up 132.21% from -$1.9 million recorded in Q2 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' EBT peaked at $621,000 during Q3 2025, and registered a low of -$50.8 million during Q4 2021.
  • Moreover, its 3-year median value for EBT was -$13.6 million (2023), whereas its average is -$11.9 million.
  • Its EBT has fluctuated over the past 5 years, first slumped by 132.37% in 2021, then spiked by 103.26% in 2025.
  • Quarterly analysis of 5 years shows Xeris Biopharma Holdings' EBT stood at -$50.8 million in 2021, then skyrocketed by 73.88% to -$13.3 million in 2022, then declined by 2.70% to -$13.6 million in 2023, then skyrocketed by 62.48% to -$5.1 million in 2024, then surged by 103.26% to $621,000 in 2025.
  • Its last three reported values are $621,000 in Q3 2025, -$1.9 million for Q2 2025, and -$9.2 million during Q1 2025.